Overweight and Obesity, Adults: Management
Covering recommendations on the prevention and management of overweight, obesity, and central adiposity in adults
Related Articles
German authorities to lift emergency ordinance to curb foot-and-mouth disease
German authorities are to lift an emergency ordinance to stop the spread of the livestock illness foot-and-mouth disease at the end of the day, the…
The US Preventive Services Task Force and Precision Prevention
This Viewpoint summarizes how the US Preventive Services Task Force specifies target populations for its recommendations and highlights 3 problems—including exacerbation of health inequities—posed by…
Meet the Company Developing an At-Home Test to Replace the Pap Smear – MedCity News
Teal Health raised $10 million in seed funding, taking its total funding to $23 million. The company has submitted an application to the FDA for…
Home – Tomorrow Bio
At Tomorrow Bio, we use the latest technology to preserve you for however long it takes until medical technology can extend your life.
How the FDA and CMS worked together on a new approach to paying for digital mental health treatments
By establishing coding and separate payment for certain digital mental health devices, this group from CMS and the FDA hopes to improve access to care.
Robotic Mitral Valve Repair: Reflections After 2,400-Plus Cases
As we mark our recent 2,400th robotic mitral valve repair, surgeons reflect on how they’ve achieved a 99.7% repair rate and operative mortality of 0.04%.
Special Issue Call for Papers: Climate Change, Worker Exposure, and Health in the Global South
Climate change is increasingly affecting workplace and environmental conditions in the Global South, putting workers at risk for increased exposures and adverse
Attributing Racial Differences in Care to Health Plan Performance or Selection
This cross-sectional study assesses whether differences across health plans in sex- and age-adjusted racial disparities are associated with performance or selection bias.
High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare
This cohort study evaluates whether patients insured by Medicare Advantage plans receive less high-cost drugs than those insured by traditional Medicare.
FDA Approves Axatilimab 9 mg and 22 mg Vial Sizes for Chronic GVHD
Axatilimab in 9 mg and 22 mg vial sizes are expected to launch in early February for the treatment of chronic graft-versus-host disease.
